Noble Financial Issues Negative Outlook for CRDF Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Noble Financial dropped their Q2 2026 earnings estimates for Cardiff Oncology in a research report issued to clients and investors on Friday, May 22nd. Noble Financial analyst R. Leboyer now expects that the company will post earnings of ($0.20) per share for the quarter, down from their prior estimate of ($0.15). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.65) per share. Noble Financial also issued estimates for Cardiff Oncology’s Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.78) EPS.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million.

A number of other research analysts have also recently commented on CRDF. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Piper Sandler decreased their target price on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Monday, May 18th. Finally, Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.10.

Cardiff Oncology Price Performance

Shares of NASDAQ CRDF opened at $1.94 on Wednesday. The business has a fifty day moving average price of $1.70 and a two-hundred day moving average price of $2.06. The stock has a market capitalization of $132.64 million, a PE ratio of -2.90 and a beta of 1.36. Cardiff Oncology has a fifty-two week low of $1.48 and a fifty-two week high of $4.56.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Brooklyn Investment Group bought a new position in shares of Cardiff Oncology in the third quarter worth about $26,000. Capital Advisors Wealth Management LLC acquired a new stake in Cardiff Oncology in the fourth quarter valued at approximately $30,000. Tamar Securities LLC bought a new stake in shares of Cardiff Oncology during the fourth quarter worth $32,000. R Squared Ltd bought a new stake in shares of Cardiff Oncology during the fourth quarter worth $36,000. Finally, Engineers Gate Manager LP acquired a new position in Cardiff Oncology in the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.